Eyenovia (EYEN)
(Delayed Data from NSDQ)
$0.58 USD
+0.04 (7.54%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $0.58 0.00 (-0.60%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EYEN 0.58 +0.04(7.54%)
Will EYEN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EYEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EYEN
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
EYEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates
ProQR (PRQR) Reports Q2 Loss, Lags Revenue Estimates
Other News for EYEN
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
12 Health Care Stocks Moving In Wednesday's Intraday Session
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
Eyenovia considers strategic alternatives, including possible sale